Patents by Inventor Ian Christopher Davis

Ian Christopher Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Liponucleotide-based therapy for asthma
    Patent number: 11850283
    Abstract: Compositions and method are therefore disclosed for treating asthma. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol in a pharmaceutically acceptable carrier for use in treating asthma.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: December 26, 2023
    Assignee: Ohio State Innovation Foundation
    Inventor: Ian Christopher Davis
  • LIPONUCLEOTIDE-BASED THERAPY FOR COPD
    Publication number: 20220062425
    Abstract: Compositions and method are therefore disclosed for treating chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis (PF). In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol in a pharmaceutically acceptable carrier for use in treating COPD and/or PF.
    Type: Application
    Filed: September 10, 2021
    Publication date: March 3, 2022
    Inventor: Ian Christopher Davis
  • Liponucleotide-based therapy for COPD
    Patent number: 11154621
    Abstract: Compositions and method are therefore disclosed for treating chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis (PF). In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol in a pharmaceutically acceptable carrier for use in treating COPD and/or PF.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 26, 2021
    Assignee: Ohio State Innovation Foundation
    Inventor: Ian Christopher Davis
  • LIPONUCLEOTIDE-BASED THERAPY FOR ARDS
    Publication number: 20210069225
    Abstract: Compositions and method are therefore disclosed for treating ARDS. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol (CDP-DAG) in a pharmaceutically acceptable carrier for use in treating ARDS.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 11, 2021
    Inventor: Ian Christopher Davis
  • Liponucleotide-based therapy for ARDS
    Patent number: 10874684
    Abstract: Compositions and method are therefore disclosed for treating ARDS. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol (CDP-DAG) in a pharmaceutically acceptable carrier for use in treating ARDS.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 29, 2020
    Assignee: Ohio State Innovation Foundation
    Inventor: Ian Christopher Davis
  • LIPONUCLEOTIDE-BASED THERAPY FOR ASTHMA
    Publication number: 20200129624
    Abstract: Compositions and method are therefore disclosed for treating asthma. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol in a pharmaceutically acceptable carrier for use in treating asthma.
    Type: Application
    Filed: June 27, 2018
    Publication date: April 30, 2020
    Inventor: Ian Christopher Davis
  • LIPONUCLEOTIDE-BASED THERAPY FOR COPD
    Publication number: 20200129623
    Abstract: Compositions and method are therefore disclosed for treating chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis (PF). In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol in a pharmaceutically acceptable carrier for use in treating COPD and/or PF.
    Type: Application
    Filed: June 27, 2018
    Publication date: April 30, 2020
    Inventor: Ian Christopher Davis
  • LIPONUCLEOTIDE-BASED THERAPY FOR ARDS
    Publication number: 20190134074
    Abstract: Compositions and method are therefore disclosed for treating ARDS. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol (CDP-DAG) in a pharmaceutically acceptable carrier for use in treating ARDS.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Inventor: Ian Christopher Davis